Publications authored by CHSPR faculty and staff from 2009 to the present are listed here. Older peer-reviewed publications are usually available from individual journals and can be searched for using PubMed. Older reports published by CHSPR (from 1973) are available from the UBC Library cIRcle database. If you cannot find a specific publication, please contact us.
Schoenbaum M, Sutherland JM, Chappel A, Azrin S, Goldstein AB, Rupp A, Heinssen RK. Twelve-Month Health Care Use and Mortality in Commercially Insured Young People With Incident Psychosis in the United States. Schizophr Bull. 2017 Apr 7. Read more
Kratzer J, Cheng L, Allin S, Law MR. The Impact of Private Insurance Coverage on Prescription Drug Use in Ontario, Canada. Healthc Policy. 2015 May;10(4):62-74. Read more
Morgan SG, Law M, Daw JR, Abraham L, Martin D. Estimated cost of universal public coverage of prescription drugs in Canada. CMAJ. 2015 Apr 21;187(7):491-7. Read more
Law MR, Kratzer J, Dhalla IA. The increasing inefficiency of private health insurance in Canada. CMAJ. 2014 Sep 2;186(12):E470-E474. Read more
Daw JR Morgan SG, Collins PA, Abelson J. Framing incremental expansions to public health insurance systems: the case of Canadian pharmacare. J Health Polit Policy Law. 2014 Apr;39(2):295-330. Read more
Sanmartin C, Hennessy D, Lu Y, Law MR. Trends in out-of-pocket health care expenditures in Canada by income, 1997 to 2009. Health Rep. 2014 Apr 16;25(4):13-7. Read more
Balaban DY, Dhalla IA, Law MR, Bell CM. Private expenditures on brand name prescription drugs after generic entry.Appl Health Econ Health Policy. 2013 Oct;11(5):523-9. Read more
Law MR, Kratzer J. The road to competitive generic drug prices in Canada. CMAJ. 2013 Sep 17;185(13):1141-4. Read more
Kratzer J, McGrail K, Strumpf E, Law MR. Cost-control mechanisms in Canadian private drug plans. Healthc Policy. 2013 Aug;9(1):35-43. Read more
Kozhimannil K, Law MR, Peterson-Blauer C, Zhang F, Wharam JF. The impact of high-deductible health plans on men and women: an analysis of emergency department care. Med Care. 2013 Aug;51(8):639-45. Read more
Morgan S, Daw J, Law M. Rethinking Pharmacare in Canada. Toronto (ON): C.D. Howe Institute; Jun 2013. Commentary no.384. Read more
Morgan SG, Friesen MK, Thomson PA, Daw JR. Use of product listing agreements by Canadian provincial drug benefit plans. Healthc Policy. 2013 May;8(4):45-55. Read more
Noble D, Biller-Andorno N, Sutherland JM, Anstey M. Challenges facing Medicaid expansion in the US. BMJ. 2013 May 29;346:f3261. Read more
Allin S, Law MR, Laporte A. How does complementary private prescription drug insurance coverage affect seniors' use of publicly funded medications? Health Policy. 2013 May;110(2-3):147-55. Read more
Law MR, Daw JR, Cheng L, Morgan SG. Growth in private payments for health care by Canadian households. Health Policy. 2013 May;110(2-3):141-6. Read more
Morgan S, Daw J, Thomson P. International best practices for negotiating 'reimbursement contracts' with price rebates from pharmaceutical companies. Health Aff (Millwood). 2013 Apr;32(4):771-7. Read more
Law MR. Money left on the table: generic drug prices in Canada. Healthc Policy. 2013 Feb;8(3):17-25. Read more
Morgan SG, Thomson PA, Daw JR, Friesen MK, Dijkstra A. The public provision of pharmaceuticals: a synthesis of policies in ten developed countries. Vancouver (BC): Pharmaceutical Policy Research Collaboration; Dec 2012. Read more
Morgan SG, Daw JR. Canadian pharmacare: looking back, looking forward. Healthc Policy. 2012 Aug;8(1):14-23. Read more
Evans RG. A Casualty in the Class War: Canada's Medicare. Healthc Policy. 2012 Feb;7(3):14-22. Read more